In order to gain access to further scientific and clinical expertise for the continued development of resomelagon (AP1189), SynAct Parma has established a Scientific council.

The Scientific council represents significant pharmacological and clinical expertise within the field of melanocortin receptors and the pharmacological aspects of inflammation healing, as well as leading clinical expertise in the field of rheumatology, with particular focus on rheumatoid arthritis.

Roy Fleischmann

Master of the American College of Rheumatology and a Clinical Professor of Medicine at the University of Texas Southwestern Medical Center, Co- Medical Director of the Metroplex Clinical Research Center and Division of Rheumatology at the Presbyterian Medical Center in Dallas.

He is an Overseas Fellow of the Royal Society of Medicine, a past President of the Texas Rheumatism Association, Division Director Rheumatology, St, Paul Medical Center.

He has been involved in the clinical development of most medications approved for rheumatic disease in the US. He has published over 300 peer-reviewed manuscripts and presented over 500 abstracts at major Rheumatology meetings on disease management and drug development

Mauro Perretti

Professor of immunopharmacology and dean of science (Dean of Research) at Barts and London School of Medicine. Prior to being appointed Scientific Dean, Professor Perretti was the co-director of the William Harvey Research Institute, one of the world’s leading pharmacological research institutions focusing on basic and translational pharmacology.

Professor Perretti has published more than 300 scientific articles and has been cited over 17,000 times. Professor Perretti is a Fellow of the British Pharmacological Society. Professor Perretti is a pioneer in understanding the role of specialized pro-resolution mediators in inflammatory processes. His laboratory is a leader in understanding the anti-inflammatory effects of the melanocortin system and has identified the melanocortin type 3 receptor as a potential target for novel innovative drug development.

Since 2012, SynAct Pharma has had a collaboration agreement with Professor Perretti’s laboratory and essential parts of the understanding of the mechanism of action of SynAct Pharma’s resomelagon (AP1189) molecule have been created in this collaboration.

Ravi Rao

Currently CMO at Sitryx Therapeutics and Venture Partner at SV Health Investors; previously a Consultant Rheumatologist at Imperial College NHS Trust, Roche: Medical Director, Immunology Clinical Development, GSK: VP, Global Medical Head, Immunology-inflammation and Future Pipeline Franchise, SOBI: Head R&D and CMO.

Vibeke Strand

Adjunct clinical professor in the Division of Immunology and Rheumatology at Stanford University School of Medicine since 1993, previously Assistant and Associate Clinical Professor of Rheumatology at UCSF. Since 1991, she has led a consulting practice offering clinical research and regulatory strategy expertise to pharmaceutical and biotech companies.

She has participated in the successful development of csDMARDs, biologics and JAK inhibitors in RA, including working with FDA, CDER, CBER and CDRH. She is a co-founder and member of the Executive Organizing Committee of the international Outcomes in Rheumatology [OMERACT] consensus conferences [1992 – present] which develop and validate outcome measures for use in RCTs and longitudinal observational studies. Vibeke Strand has authored > 500 peer-reviewed publications.

Mauro Teixeira

Professor of Immunology and Head of the Center for Advanced and Innovative Therapies of the Federal University of Minas Gerais (UFMG) in Brazil. UFMG is one of the leading Universities of Latin America with a long standing tradition of work in Tropical medicine and other infectious diseases.

Professor Teixeira has published more than 680 scientific articles (PubMed) and has been cited over 39,000 times (Google Scholar). Professor Teixeira is a member of the Brazilian Academy of sciences, the World Academy of Sciences (TWAS) and a Fellow of the British Pharmacological Society. He is currently Secretary of the Immunopharmacology committee of the International Union of Basic and Clinical Pharmacology (IUPHAR) , Head of the Immunotherapy committee of the International Union of Immunological Societies (IUIS) and Secretary of the International Association of Inflammation Societies (IAIS).

Professor Teixeira has done pioneering work in defining the relevance of specialized pro-resolution mediators in models of inflammation in vivo and defining the relevance of these molecules in the context of infectious diseases. His laboratory has described several mediators with defined pro-resolving activity, including angiotensin 1-7, plasmin/plasminogen and short-chain fatty acids.

Since 2020, SynAct Pharma has had a collaboration agreement with Professor Teixeira’s laboratory to investigate the effects of SynAct Pharma’s resomelagon (AP1189) molecule in the context of COVID-19.